Scienture Holdings Inc. Common Stock (SCNX)

FairStock Score: 37/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I approach Scienture as a Graham-style analyst: until a business shows durable earning power, price is speculation. Scienture is a four-employee pharmaceutical developer with pipeline assets in central nervous system and cardiovascular disease. The filed figures are stark. In fiscal Q2 2026, the quarter ended 2026-06-30, revenue was $343,639 and net loss was $2.8 million. In fiscal Q1 2026, the quarter ended 2026-03-31, revenue was $56,325 and net loss was $3.4 million. For FY2025, the year ended 2025-12-31, revenue was $431,609 and net loss was $41.5 million, versus FY2024, ended 2024-12-31, net income of $9.1 million on revenue of $136,643. That swing puts it in FairStock's TURNAROUND category—loss in the latest year after earlier profits—but a turnaround is not a moat. Trailing free cash flow is -$15.5 million, a -11.7% FCF yield. FairStock calculations show ROE of -53.47%, ROCE of -8.93%, D/E of 0.17, Piotroski of 4/9, and Altman Z of 1.98. At the $3.24 close on 2026-10-13, market cap is $133.0 million; FairStock calculations put P/B at 2.08, P/E at -1.60, and beta at 3.98. The market is paying a book-value multiple for almost no revenue and heavy losses. Phase 1 products may offer optionality, but they require cash and time. I see no margin of safety in these numbers.

In plain English: Scienture Holdings is a tiny drug company trying to develop treatments for brain and heart conditions. It earns very little money and is losing millions, with only a few employees, so the business looks weak today. At the recent price, the stock looks expensive compared with its tiny sales and losses.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer